The USFDA sends the applicant a CRL if the agency determines that it will not approve the application, or ANDA, in its present form for one or more reason
Shares of Dr Reddy's Laboratories fell 1.8 percent intraday on August 16 after the management issued a clarification after receiving a Complete Response Letter (CRL) from the US health regulator over its NuvaRing drug.
The stock had shed 1.8 percent on August 14 on street's expectations of a likely delay in the launch of NuvaRing drug. At 13:06 hours IST, the stock ...
Read the full text moneycontrol